The Latest on Drug Policies T. Joseph Mattingly II Laura Tollen January 21, 2026

https://www.healthaffairs.org/do/10.1377/he20251210.32037/full/?utm_campaign=insidermarketing&utm_medium=email&_hsenc=p2ANqtz-_rayR6jOC0-B5DNJVWXLT62YVvcu2Q8FKLn0Qvw4PqSNhfSQGP1KcNcqFDX80byEW3uNiqPulEDv9RoLbFohpZewOJgA&_hsmi=397777203&utm_content=eventspecific&utm_source=hasu Join Health Affairs on January 21 for an exclusive Insider virtual event exploring the latest drug policies with the University of Utah’s Joey Mattingly. This event is for Health Affairs Insiders only. There was a lot of movement in the drug policy space late in 2025. CMS announced a new drug payment model and touted $12 billion in savings from 2024 under the drug price negotiation program under the IRA. And, the Trump administration made deals with major pharmaceutical companies Novo Nordisk, Eli Lilly, and Pfizer over the price of GLP-1 weight-loss drugs. Joey Mattingly from the University of Utah College of Pharmacy will join Health Affairs’ Laura Tollen to get Insiders up to speed on the latest drug policy developments and what to expect later in 2026.